The US Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) for Granules India's Jeedimetla facility located at Hyderabad, Telangana, India. This facility was inspected by USFDA in March 2018 and there was one (1) 483 observation during the inspection. The company has responded to the observation within the stipulated timeframe. Jeedimetla facility manufactures Active pharmaceutical ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).